■HANDOK Pharmaceutical Museum announced on the 18th that it is recruiting participants for its summer vacation program. Participants will view the 'Donguibogam' first edition by Heo Jun and the 'German Pharmacy,' a recreation of a 19th-century German pharmacy, and receive explanations. Elementary school students will learn how to take medication from pharmacists and have hands-on experience making pills today as a pharmacist. Young children and lower-grade elementary students will make simple stethoscopes to understand the human body. The program will be held concurrently at HANDOK Pharmaceutical Museum in Eumseong, Chungbuk, and Seoul from July 25 to August 17. The HANDOK Pharmaceutical Museum, established in 1964, is the first corporate museum in the country.
■The Korea Breast Cancer Patients Association (KBPPA) announced on the 18th that it will hold a health lecture for breast cancer patients and their guardians on the 3rd of next month at The Hue Wedding Hall in Samseong-dong, Gangnam-gu, Seoul. The topic will be 'Pink Ribbon Hope Lecture: From Diagnosis to Treatment and Healthy Diet,' providing health and dietary information. Professor Hong Ji-hyeong from the National Cancer Center will give a lecture on 'Understanding My Type of Breast Cancer: Diagnosis and Classification of Breast Cancer.' Professor Ahn Hee-kyung from Samsung Medical Center will present on 'What Is HER2 Low-Expressing Breast Cancer, Which Affects 50% of Breast Cancer Patients?' Clinical nutritionist Kim Young-ran from Seoul National University Boramae Hospital will introduce 'Beautiful and Healthy Me! Nutritional Management to Overcome Breast Cancer.' Pre-registration can be done via the email of KBPPA (ukbcp2011@daum.net). The lecture can also be accessed on the KBPPA YouTube channel.
■The Ministry of Health and Welfare and Boryung announced on the 18th that they plan to re-launch a hyperlipidemia treatment for mothers and newborns after two years. Boryung produced a hyperlipidemia treatment (Boryung Questran suspension) that can be safely used by mothers and newborns, but domestic production was suspended in 2023 due to worsening profitability. However, selected as the first executing institution for the Ministry's 'Support Project for the Production of Pharmaceuticals with Supply Instability,' they can now resume production. This is a government-supported project for the production facilities and equipment of pharmaceuticals that are not easily available in the domestic market. Boryung plans to resume product launches within the year.
■Samsung Medical Center's Department of Pediatrics and Adolescent Medicine announced on the 18th that it will hold a 'Korea-Japan Primary Immunodeficiency International Symposium' on the 29th. Experts in primary immunodeficiency diseases and genetics from Korea and Japan will be invited to share research trends and experiences. Primary immunodeficiency diseases manifest a variety of symptoms, making diagnosis and treatment challenging. Professor Kim Ye-jin from Samsung Medical Center stated, "For complex and rare diseases like immunodeficiency, collaboration between clinical medicine, basic science, and genetics is essential."
■Dong-A ST announced on the 18th that it has signed a business agreement with Hebron Medical Center in Phnom Penh, Cambodia, to support the remote patient monitoring platform 'Hi-Cardi.' This platform will allow for remote management of patients in Cambodia, where healthcare is lacking, contributing to early disease detection and patient survival. Dong-A ST has been donating specialty pharmaceuticals to Cambodia since 2018 and plans to provide education to local medical personnel annually while supporting Canbacas and Oratte beverages.
■Chung-Ang University Hospital announced on the 18th that it has been selected for the 'Service Robot' demonstration project led by the Korea Institute for Robot Industry Advancement under the Ministry of Trade, Industry and Energy. Chung-Ang University Hospital, in cooperation with the medical robotics company CUREXO, will introduce the spinal surgery robot 'CUBIS Spine CS200,' which guides surgical tools with precision. The hospital reports that it expects to reduce the risk of complications during surgery and shorten hospital stays.
■Korea University Guro Hospital announced on the 18th that Professor Dong Eun-sang from the Department of Plastic Surgery has published a book titled 'Nasal Surgery for Asians: Septal Extension Surgery.' The book contains clinical cases and know-how related to septal rhinoplasty for Asians. Professor Dong noted, "The approach to rhinoplasty for Asians should differ from that for Westerners and must be based on the anatomical characteristics and aesthetic sense of Asians."
■Dong-A Pharmaceutical announced on the 18th that it will introduce a topical alopecia treatment, 'Capillus Foam Aerosol.' The product contains minoxidil and is a non-prescription medication. The foam form prevents dripping from the scalp. The Company enhanced the foam's density to improve retention. It has addressed the issue of varying consistency with temperature, making it comfortable to use even in summer.
■JW Pharmaceutical announced on the 18th that it has introduced 'Melamind,' which contains plant-based melatonin for sleep health. Melatonin is a hormone secreted by the brain that induces sleep and regulates the biological rhythm. As melatonin secretion decreases with aging, difficulties in sleeping may arise. Melamind contains 100% plant-based melatonin (2 mg) extracted from American pistachios, along with probiotics, folic acid, and chamomile.
■Celltrion announced on the 18th that the 40-week results of the global phase 3 trial of CT-P39 (Omniclon) have been published in the international journal Clinical & Translational Allergy (CTA). CT-P39 is a biosimilar of Xolair (active ingredient omalizumab) used for asthma and urticaria. Xolair was developed by Genentech and Novartis, recording sales of approximately 6 trillion won last year. The company treated 619 patients with chronic idiopathic urticaria for 24 weeks and followed up for 16 weeks, confirming its efficacy and safety.
■GC Genome announced on the 18th that 'iCancerCh' technology for screening multiple cancers using artificial intelligence (AI) has been registered as a foundational patent in Japan. This technology allows for the early detection of lung cancer, liver cancer, colorectal cancer, pancreaticobiliary cancer, esophageal cancer, and ovarian cancer from a single blood draw. The core technology, FEMS, can capture subtle cancer cell signals from blood. The self-developed AI algorithm analyzes nucleotide fragment sizes and end-base sequence patterns of cell-free DNA.
■Hanmi Pharmaceutical announced on the 18th that it has donated 10 million won of revenue generated from its YouTube channel 'Doctor in My Ear' to patients. Since 2019, the company has been operating a YouTube channel that provides public information on diseases. Medical specialists explain medical information in an easily understandable manner, aiding in early diagnosis and treatment.
■Dongkook Pharmaceutical announced on the 18th that it will introduce the 'Madecassan All-Day Summer Edition' of its dermaceutical brand Centellian24. This summer limited edition consists of Madecass cream and Madecass cream tight lifting. Madecass cream protects the skin from harsh midday sun exposure. Madecass cream tight lifting helps with elasticity and lifting.
■Dong Kook Lifescience announced on the 18th that it has received approval for the phase 3 clinical trial plan for 'INV-002', which 인벤테라 is developing. INV-002 is a new candidate for MRI (Magnetic Resonance Imaging) contrast agents specialized for musculoskeletal conditions, aiding in the diagnosis of shoulder joint diseases. The phase 3 clinical trial will be conducted on 85 patients suffering from conditions such as rotator cuff tears, cartilage damage, and frozen shoulder at eight university hospitals. Dong Kook Lifescience has formed a strategic partnership with Inventa.